Latest News

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

Pharmacists who understand both the clinical and the contractual dimensions of these policies are positioned to translate between the payer's cost logic and the provider's patient safety argument.

A study found worsening chronic kidney disease (CKD) severity was independently associated with increased mortality risk and exponentially higher rates of kidney replacement therapy initiation following ICU admission.

A systematic review of 23 randomized trials suggests melatonin may modestly reduce musculoskeletal pain and improve sleep, although pharmacists should emphasize uncertain dosing, supplement quality, and the need to use it only as an adjunct to individualized pain care.

Candel Therapeutics has launched the global phase 3 AURORA trial to evaluate investigational viral immunotherapy in patients with advanced non-small cell lung cancer.

Messenger RNA vaccines were effective against any documented SARS-CoV-2 infection, against hospitalization, and against mortality within 14 to 42 days of vaccination.

The POSEIDON clinical trial shows that high-sensitivity C-reactive protein levels remain elevated in approximately 2 in 5 patients with CVD, pointing to a gap in residual inflammatory risk management.

COVID-19 boosters can also neutralize certain bat and pangolin coronaviruses, while immune "imprinting" from a person's first viral exposure limits how well that protection adapts to newer variants.

Only 3 uncontrolled pilot studies with a combined sample size of 30 participants have been reported for BPC-157.

Tregzi is indicated in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen for hematopoietic and immunologic reconstitution and to improve chronic graft-vs-host disease–free survival.

As OTC drink-spiking detection products become more widely available, pharmacists can play a critical role in counseling patients on their benefits, limitations, and appropriate response to suspected drink tampering.

The FDA clears roflumilast, a PDE4 inhibitor, for once-daily steroid-free plaque psoriasis care in kids ages 2+.

Findings from a multicenter cohort study suggest glucagon-like peptide-1 (GLP-1) receptor agonist therapy may be associated with an elevated risk of sensory disturbances.

The approval adds a 55-mg prefilled syringe for weight-based dosing and makes risankizumab the first IL-23 inhibitor cleared for pediatric patients weighing less than 40 kg.

Findings from EPCORE DLBCL-4 show that fixed-duration epcoritamab plus lenalidomide significantly improved progression-free survival (PFS) versus R-GemOx in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The blood test offers a promising new approach to identify patients who are at high risk for recurrence and guide precision treatment strategies.

Pharmacist-led MTM services can deliver measurable clinical and financial value while advancing patient-centered care.

Oncology Pharmacists Connect 2026 emphasized the pharmacist’s role in translating rapidly evolving evidence into patient-centered, operationally feasible cancer care.

AML and menin inhibitors transform acute myeloid leukemia treatment: FDA-approved choices, MEN1 protein target, and bedside toxicity monitoring.

PCOS becomes PMOS, spotlighting metabolic and endocrine risks.

Be confident that you have researched all avenues and feel secure in making your recommendations.